Skip to main content

Table 1 Outcome at 6 months (percent data) from major pharmacological trials and consecutive series

From: Chronic impact of traumatic brain injury on outcome and quality of life: a narrative review

  Publication year Patient number Death Vegetative state Severe disability Moderate disability Good recovery
Neuroprotective trials: placebo groups
Tirilazad [82] 1998 459 28 4 13 17 38
Metilprednisolone [48] 2005 4819 22 Included in the mortality rate 14 17 46
Progesteron [83] 2014 588 22 Not reported 27 19 31
Consecutive series
EBIC [84] 1999 796 31 2 16 20 31
NeuroLink [85] 2012 1273 33 3 14 17 33
UK RAIN study [86] 2013 2620 26 Not reported 33 22 19
  1. Results at 6 months shown in this table are not corrected for severity. Better results in the neuroprotective trials may depend on the exclusion of the most severe cases, who are not amenable to randomization but are, on the contrary, included in consecutive series. The Metilprednisolone study included severe and moderate TBI
\